<DOC>
	<DOCNO>NCT03026946</DOCNO>
	<brief_summary>The purpose study compare efficacy alitretinoin cyclosporine treatment patient severe recurrent vesicular hand eczema .</brief_summary>
	<brief_title>Alitretinoin v Cyclosporine Severe Recurrent Vesicular Hand Eczema</brief_title>
	<detailed_description />
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Alitretinoin</mesh_term>
	<criteria>Age ≥ 18 year ≤ 75 year Severe severe recurrent vesicular hand eczema minimum duration 3 month define Physician Global Assessment ( PGA ) use validate Photoguide Refractory standard therapy , define : Patients receive treatment topical corticosteroid class II high least 8 week within 3 month enrolment , either response transient response . Patients also receive standard skin care , include emollient barrier protection appropriate , without significant improvement . Patients avoid irritant contact allergen , identify , without significant improvement . Women childbearing potential require use least two form contraception least 1 month start treatment , treatment , least 1 month finishing treatment ; woman require take monthly pregnancy test Able provide write Informed Consent Able speak read Dutch language General criterion prior randomization Treated alitretinoin cyclosporine previous 3 month Other morphologic type hand eczema define Danish Contact Dermatitis Group Patients predominantly atopic dermatitis , hand also involve . ( Patients control atopic dermatitis , hand mainly affect , eligible inclusion . ) Psoriasis hand Active bacterial , fungal , viral infection hand Pregnant/lactating plan become pregnant study period Treatment systemic medication UV radiation within previous 4 week Mentally incompetent Immunocompromised status Uncontrolled arterial hypertension ( minimally 3 measurement ) . Systolic pressure &gt; 160 mmHg diastolic pressure &gt; 95 mmHg , despite start antihypertensive medication ( first choice amlodipine 5 mg/day ) Known suspect allergy ingredient study medication Inclusion study investigational drug within 60 day prior start treatment Current malignancy ( successfully treat nonmetastatic cutaneous squamous cell basal cell carcinoma and⁄or localize carcinoma situ cervix ) Current active pancreatitis Evidence alcohol abuse drug addiction Malabsorption Currently active gout Recurring convulsion / epilepsy Living vaccine ( include bacillus CalmetteGuérin ( BCG ) , varicella , measles , mumps , rubella , yellow fever , oral polio oral typhoid ) last 2 week plan application vaccine study period Chronic recurrent infectious disease Contact sensitization clinical relevance hand , exposure allergen avoid . Hypervitaminosis A due use vitamin A supplement contain &gt; 2000 IU Use drug potential change effective dosis study drug within previous 2 week Laboratory exclusion criterion post randomization Alanine aminotransferase ( ALAT ) ⁄or aspartate aminotransferase ( ASAT ) value &gt; 200 % upper limit normal Impaired renal function indicate clinically relevant abnormal creatinine value ( determined investigator treat physician ) Anemia indicate clinically relevant lower hemoglobin value ( determined investigator treat physician ) Alitretinoin specific Triglycerides &gt; 200 % upper limit normal , Cholesterol low density lipoprotein ( LDL ) cholesterol value &gt; 200 % upper limit normal Uncontrolled hypothyroidism ( determined investigator treat physician ) Cyclosporine specific : Impaired renal function indicate clinically relevant abnormal creatinine value ( determined investigator treat physician ) Uremia Hyperkalemia Hyperuricemia patient medical history gout</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Alitretinoin</keyword>
	<keyword>Cyclosporine A</keyword>
	<keyword>Hand eczema</keyword>
</DOC>